Ascletis OKd for Phase IIa Clinical Trial for ASC10 to Treat Respiratory Syncytial Virus

 

• Respiratory syncytial virus (RSV) infection treatment remains huge unmet medical needs and there is no effective drug for treatment globally so far
• Dosage of 800 mg ASC10, twice daily was selected to conduct a Phase IIa study in patients with RSV infection
• Preclinical research showed that ASC10-A is a potent inhibitor against RSV both in vitro and in vivo

https://www.biospace.com/article/releases/ascletis-announces-u-s-fda-approval-of-conducting-a-phase-iia-clinical-trial-for-asc10-to-treat-respiratory-syncytial-virus-infection/